Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-04-10
2007-04-10
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S006120, C435S069100, C530S300000
Reexamination Certificate
active
10472724
ABSTRACT:
Described are DNA sequences encoding an E6 or E7 fusionprotein of HPV, wherein said DNA sequences are characterized by a combination of the following features: original codons are exchanged by codons which lead to an enhanced translation in a mammalian cell, they contain a deletion resulting in the production of a truncated non-functional protein, and they encode a fusionpartner which is a highly immunogenic polypeptide capable of enhancing the immunogenicity of the E6 or E7 protein in the mammalian host. Furthermore, the modified E6 or E7 protein encoded by said DNA sequences as well as expression vectors containing said DNA sequences are described as well as several uses of the these compounds.
REFERENCES:
patent: 0 271 302 (1988-06-01), None
patent: WO 99/10375 (1999-04-01), None
patent: WO 99/55876 (1999-11-01), None
patent: WO 01/14416 (2001-03-01), None
patent: WO 01/17551 (2001-03-01), None
Smahel, Michal, et al., “Modified HVPV16 E7 Genes as DNA Vaccine Against E-7-Containing Oncogenic Cells”, Virology 281, 231-238 (2001).
Boursnell, M.E.G., et al., “Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer”, Vaccine, vol. 14, No. 16, patent. 1485-1494 (1996).
Lipari, Francesco, et al., “Purification and Biophysucal Characterization of a Minimal Functional Domain and of an N-Terminal Zn2+-Binding Fragment from the Human Papillomavirus Type 16 E6 Protein”, Biochemistry 2001, 40, 1196-1204 (2001).
Zhou, Jian, et al., Papillomavirus Capsid Protein Exprssion Level Depends on the Match between Codon Usage and tRNA Availabiality, Journal of Virology, 4972-4982, (Jun. 1999).
Smahel, Michal, et al. “Modified HPV 16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells.” Virology, (2001), vol. 281, pp. 231-238.
Daemen, Toos, et al. “Eradication of established HPV 16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7.” Vaccine, (2003), vol. 21, pp. 1082-1088.
Liu, Wen Jun, et al. “Codon Modified Human Papillomavirus Type 16 E7 DNA Vaccine Enhances Cytotoxic T-Lymphocyte Induction and Anti-tumor Activity.” Virology, (2002), vol. 301, pp. 43-52.
Cid-Arregui Angel
Hausen Harald Zur
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Recht
Hultquist Steven J.
Intellectual Property / Technology Law
LandOfFree
Modified HPV E6 and E7 genes and proteins useful for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified HPV E6 and E7 genes and proteins useful for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified HPV E6 and E7 genes and proteins useful for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3743162